Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keri A Kles

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Current Diabetes Reviews|January 29, 2008
Diagnostic tools for diabetic sensorimotor polyneuropathyKeri A Kles, Vera Bril
Current Diabetes Reviews|January 29, 2008
Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential componentKeri A Kles, Aaron I Vinik
Expert Review of Endocrinology & Metabolism|February 13, 2019
Role of protein kinase C inhibition in the development of diabetic microvascular complicationsVladimir Skljarevski, Sarah J Ferdinand, Keri A Kles
Endocrine|November 10, 2007
How the diabetic eye loses visionJaime A Davidson, Thomas A Ciulla, Janet B McGill, et al.
Diabetes Care|July 12, 2007
Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trialsSolomon Tesfaye, Rup Tandan, Edward J Bastyr, et al.
Retina (Philadelphia, Pa.)|March 10, 2011
Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)Matthew J Sheetz, Lloyd Paul Aiello, Nazila Shahri, et al.
Inflammatory Bowel Diseases|March 1, 2005
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileumKeri A Kles, Stephan R Vavricka, Jerrold R Turner, et al.
Expert Opinion on Drug Safety|October 19, 2006
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurinJanet B McGill, George L King, Paul H Berg, et al.
Ophthalmology|September 23, 2006
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy, Lloyd Paul Aiello, Matthew D Davis, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|December 23, 2006
fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protectionRyan M Carlson, Stephan R Vavricka, Jyrki J Eloranta, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Current Diabetes Reviews|January 29, 2008
Diagnostic tools for diabetic sensorimotor polyneuropathyKeri A Kles, Vera Bril
Current Diabetes Reviews|January 29, 2008
Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential componentKeri A Kles, Aaron I Vinik
Expert Review of Endocrinology & Metabolism|February 13, 2019
Role of protein kinase C inhibition in the development of diabetic microvascular complicationsVladimir Skljarevski, Sarah J Ferdinand, Keri A Kles
Endocrine|November 10, 2007
How the diabetic eye loses visionJaime A Davidson, Thomas A Ciulla, Janet B McGill, et al.
Diabetes Care|July 12, 2007
Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trialsSolomon Tesfaye, Rup Tandan, Edward J Bastyr, et al.
Retina (Philadelphia, Pa.)|March 10, 2011
Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2)Matthew J Sheetz, Lloyd Paul Aiello, Nazila Shahri, et al.
Inflammatory Bowel Diseases|March 1, 2005
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileumKeri A Kles, Stephan R Vavricka, Jerrold R Turner, et al.
Expert Opinion on Drug Safety|October 19, 2006
Clinical safety of the selective PKC-beta inhibitor, ruboxistaurinJanet B McGill, George L King, Paul H Berg, et al.
Ophthalmology|September 23, 2006
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy, Lloyd Paul Aiello, Matthew D Davis, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|December 23, 2006
fMLP induces Hsp27 expression, attenuates NF-kappaB activation, and confers intestinal epithelial cell protectionRyan M Carlson, Stephan R Vavricka, Jyrki J Eloranta, et al.
Pageof 1